Report from Annual General Meeting

Report from Annual General Meeting

At Vitrolife's Annual General Meeting yesterday, May 3, the following, amongst
other things, was decided:

•No dividend will be paid for the financial year 2006. 

•Re-election of Board members Patrik Tigerschiöld, Madeleine Olsson-Eriksson and
Semmy Rülf and new election of Fredrik Mattsson, in accordance with the election
committee's proposal. 

•Öhrlings PricewaterhouseCoopers was elected as the new auditor, with the
authorized public accountant Birgitta Granquist with the main responsibility,
for a mandate period of four years. 

•Authorization for the Board, for the time up until the next Annual General
Meeting and on one or more occasions, to take a decision on the issue of a
maximum of 1,900,000 shares in total, corresponding to approximately 9.6 percent
of the company's share capital. The issue may deviate from the shareholders'
pre-emptive rights through a non-cash issue, through offsetting or may otherwise
be subscribed for in accordance with chapter 13 § 5, paragraph one, 6, of the
Companies Act. The reason for the possible deviation from the shareholders'
pre-emptive rights is to prepare the ground for a possible company acquisition.

•The Board was authorized to take a decision, up until the next Annual General
Meeting and on one or more occasions, with regard to the acquisition of the
company's own shares. 

•The proposed principles for remuneration and other conditions of employment for
the senior management were approved.


At the Board meeting following election which was held after the Annual General
Meeting, Patrik Tigerschiöld was elected Chairman of the Board.



May 4, 2007
Gothenburg, Sweden

The Board




Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced one-time instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation product
area works with solutions and systems to maintain tissue in optimal condition
outside the body for the required time while waiting for transplantation. The
Stem Cell Cultivation product area works with media and instruments to enable
the use and handling of stem cells for therapeutic purposes. 
     Vitrolife today has approximately 120 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.